Article
Benefit of imatinib adjuvant therapy for patients with intermediate risk gastrointestinal stromal tumor: a multi-center retrospective analysis in China
2019-12-11
Abstract excerpt
<title>Abstract</title> <p>Background The benefit of postoperative imatinib therapy on intermediated risk gastrointestinal stromal tumor patients were still under debate. Thus, the present study aims to investigate the impact of imatinib adjuvant therapy on the prognosis of intermediate risk gastrointestinal stromal tumor patients.Methods From January 2000 to April 2018, a total of 450 intermediate risk gastroint...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 3d4522f0-f75a-5d8d-abf8-a62238e3d67d
- DOI
- 10.21203/rs.2.18623/v1
